AOCNP (Advanced Oncology Certified Nurse
Practitioner) WITH CORRECT ACTUAL
QUESTIONS AND CORRECTLY WELL DEFINED
ANSWERS LATEST ALREADY GRADED A+
(2025/2026)
Section 1: Chemotherapy & Targeted Therapy Principles (Questions 1-
15)
Question 1
A patient receiving doxorubicin is at highest risk for which toxicity?
• A) Nephrotoxicity
• B) Cardiotoxicity
• C) Pulmonary fibrosis
• D) Ototoxicity
Correct ,,,,Answer,,,,: B) Cardiotoxicity
Rationale: Anthracyclines like doxorubicin are dose-dependent
cardiotoxins causing cardiomyopathy and heart failure. The risk increases
with cumulative doses above 400-450 mg/m², and lifetime cumulative
doses should not exceed 550 mg/m² (450 mg/m² if prior chest radiation).
Cardiac monitoring with MUGA or echocardiogram is required before each
dose .
,Question 2
Which laboratory value is most critical to check before administering
myelosuppressive chemotherapy?
• A) Platelet count
• B) Serum calcium
• C) Hemoglobin A1C
• D) Amylase
Correct ,,,,Answer,,,,: A) Platelet count
Rationale: Platelet count determines bleeding risk and safety for
chemotherapy administration. A platelet count <50,000/mm³ typically
requires dose modification or treatment delay. ANC also determines
infection risk. Both are critical pre-chemotherapy labs .
Question 3
A patient with tumor lysis syndrome is expected to have which lab
abnormality?
• A) Hypercalcemia
• B) Hypokalemia
• C) Hyperuricemia
• D) Hypoglycemia
Correct ,,,,Answer,,,,: C) Hyperuricemia
Rationale: Rapid cell lysis releases purines that are metabolized to uric
acid, leading to hyperuricemia. TLS also causes hyperkalemia,
hyperphosphatemia, and secondary hypocalcemia (due to calcium
,binding with phosphate). This is an oncologic emergency requiring
aggressive hydration, allopurinol or rasburicase, and close monitoring .
Question 4
A patient receiving oxaliplatin reports tingling and numbness in hands and
throat worsened by cold exposure. How should the AOCNP manage this?
• A) Grade 4 peripheral neuropathy; permanently discontinue
oxaliplatin
• B) Grade 1 acute neuropathy; continue therapy without dose
reduction
• C) Grade 2 chronic neuropathy; reduce dose by 25%
• D) Grade 3 acute neuropathy; hold oxaliplatin until resolution
Correct ,,,,Answer,,,,: B) Grade 1 acute neuropathy; continue therapy
without dose reduction
Rationale: Oxaliplatin causes a unique acute cold-induced neuropathy
(pharyngolaryngeal dysesthesia) AND a chronic cumulative peripheral
neuropathy. Acute neuropathy resolves completely between cycles and
does not interfere with ADLs, so it is Grade 1. Management involves
patient education to avoid cold drinks, cold objects, and cold
environments. No dose reduction is needed for Grade 1 acute
neuropathy .
Question 5
A patient with metastatic non-small cell lung cancer (NSCLC) with an
, EGFR exon 19 deletion is started on osimertinib. What is the most critical
adverse effect to educate the patient to report immediately?
• A) Grade 1 diarrhea
• B) Dry skin and rash
• C) Shortness of breath or chest pain
• D) Mild paronychia
Correct ,,,,Answer,,,,: C) Shortness of breath or chest pain
Rationale: Osimertinib is a 3rd-generation EGFR-TKI. While rash and
diarrhea are common, the most critical and potentially fatal adverse
effect is Interstitial Lung Disease (ILD)/Pneumonitis, which presents as
acute shortness of breath, cough, or chest pain. Patients must seek
emergency care if these occur; the drug must be permanently
discontinued if ILD is confirmed .
Question 6
A patient with HER2-positive metastatic breast cancer is receiving
pertuzumab, trastuzumab, and docetaxel (TCH). Why is a baseline
echocardiogram required?
• A) Pertuzumab causes irreversible peripheral neuropathy
• B) Docetaxel causes dose-limiting cardiotoxicity
• C) Dual HER2 blockade increases risk of left ventricular dysfunction
• D) Trastuzumab causes pulmonary fibrosis
Correct ,,,,Answer,,,,: C) Dual HER2 blockade increases risk of left
ventricular dysfunction
Practitioner) WITH CORRECT ACTUAL
QUESTIONS AND CORRECTLY WELL DEFINED
ANSWERS LATEST ALREADY GRADED A+
(2025/2026)
Section 1: Chemotherapy & Targeted Therapy Principles (Questions 1-
15)
Question 1
A patient receiving doxorubicin is at highest risk for which toxicity?
• A) Nephrotoxicity
• B) Cardiotoxicity
• C) Pulmonary fibrosis
• D) Ototoxicity
Correct ,,,,Answer,,,,: B) Cardiotoxicity
Rationale: Anthracyclines like doxorubicin are dose-dependent
cardiotoxins causing cardiomyopathy and heart failure. The risk increases
with cumulative doses above 400-450 mg/m², and lifetime cumulative
doses should not exceed 550 mg/m² (450 mg/m² if prior chest radiation).
Cardiac monitoring with MUGA or echocardiogram is required before each
dose .
,Question 2
Which laboratory value is most critical to check before administering
myelosuppressive chemotherapy?
• A) Platelet count
• B) Serum calcium
• C) Hemoglobin A1C
• D) Amylase
Correct ,,,,Answer,,,,: A) Platelet count
Rationale: Platelet count determines bleeding risk and safety for
chemotherapy administration. A platelet count <50,000/mm³ typically
requires dose modification or treatment delay. ANC also determines
infection risk. Both are critical pre-chemotherapy labs .
Question 3
A patient with tumor lysis syndrome is expected to have which lab
abnormality?
• A) Hypercalcemia
• B) Hypokalemia
• C) Hyperuricemia
• D) Hypoglycemia
Correct ,,,,Answer,,,,: C) Hyperuricemia
Rationale: Rapid cell lysis releases purines that are metabolized to uric
acid, leading to hyperuricemia. TLS also causes hyperkalemia,
hyperphosphatemia, and secondary hypocalcemia (due to calcium
,binding with phosphate). This is an oncologic emergency requiring
aggressive hydration, allopurinol or rasburicase, and close monitoring .
Question 4
A patient receiving oxaliplatin reports tingling and numbness in hands and
throat worsened by cold exposure. How should the AOCNP manage this?
• A) Grade 4 peripheral neuropathy; permanently discontinue
oxaliplatin
• B) Grade 1 acute neuropathy; continue therapy without dose
reduction
• C) Grade 2 chronic neuropathy; reduce dose by 25%
• D) Grade 3 acute neuropathy; hold oxaliplatin until resolution
Correct ,,,,Answer,,,,: B) Grade 1 acute neuropathy; continue therapy
without dose reduction
Rationale: Oxaliplatin causes a unique acute cold-induced neuropathy
(pharyngolaryngeal dysesthesia) AND a chronic cumulative peripheral
neuropathy. Acute neuropathy resolves completely between cycles and
does not interfere with ADLs, so it is Grade 1. Management involves
patient education to avoid cold drinks, cold objects, and cold
environments. No dose reduction is needed for Grade 1 acute
neuropathy .
Question 5
A patient with metastatic non-small cell lung cancer (NSCLC) with an
, EGFR exon 19 deletion is started on osimertinib. What is the most critical
adverse effect to educate the patient to report immediately?
• A) Grade 1 diarrhea
• B) Dry skin and rash
• C) Shortness of breath or chest pain
• D) Mild paronychia
Correct ,,,,Answer,,,,: C) Shortness of breath or chest pain
Rationale: Osimertinib is a 3rd-generation EGFR-TKI. While rash and
diarrhea are common, the most critical and potentially fatal adverse
effect is Interstitial Lung Disease (ILD)/Pneumonitis, which presents as
acute shortness of breath, cough, or chest pain. Patients must seek
emergency care if these occur; the drug must be permanently
discontinued if ILD is confirmed .
Question 6
A patient with HER2-positive metastatic breast cancer is receiving
pertuzumab, trastuzumab, and docetaxel (TCH). Why is a baseline
echocardiogram required?
• A) Pertuzumab causes irreversible peripheral neuropathy
• B) Docetaxel causes dose-limiting cardiotoxicity
• C) Dual HER2 blockade increases risk of left ventricular dysfunction
• D) Trastuzumab causes pulmonary fibrosis
Correct ,,,,Answer,,,,: C) Dual HER2 blockade increases risk of left
ventricular dysfunction
